What every interventional cardiologist should know about new cardiovascular drugs

Facilitators: A. Pathak, P. Steg

Speakers: A. Pathak, P. Steg

Summary

Consult this session to learn all about the impact of new cardiovascular drugs in patients with coronary artery disease, diabetes and other high-risk conditions, such as PCSK9 and SGLT-2 inhibitors, GLP1 agonists, and more!

Learning Objectives

You need to be fully aware of the major impact of several new drugs on cardiovascular outcomes in patients with coronary artery disease, diabetes and other high-risk conditions

Presentations available when logged in:

PCSK9 anti-cholesterol drugs
Anti-diabetic drugs (SGLT-2 inhibitors and GLP1 agonists)
Anti-thrombotic drugs

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

What every interventional cardiologist should know about new cardiovascular drugs

Learning Objectives

Log in or create account for free